Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Eun-Young | - |
dc.contributor.author | Hong, Jihyung | - |
dc.contributor.author | Bae, SeungJin | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | An, Hyonggin | - |
dc.contributor.author | Hwang, Eun-joo | - |
dc.contributor.author | Lee, Seung-min | - |
dc.contributor.author | Lee, Tae-jin | - |
dc.date.accessioned | 2022-06-25T05:40:08Z | - |
dc.date.available | 2022-06-25T05:40:08Z | - |
dc.date.created | 2022-04-06 | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 1175-5652 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84797 | - |
dc.description.abstract | The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstances, the Health Insurance Review and Assessment Service published the third version in January 2021. This article reviews the revision process and major changes made in the new edition of the PE guidelines. The revision was processed through reviews of the previous 50 PE submissions, international guidelines, academic literature, and surveys and advisory meetings to obtain stakeholders' opinions. The analysis perspective has changed from a limited societal perspective to a healthcare system perspective. In addition to the drug with the highest market share, drugs used in clinical trials can be selected as comparators under certain conditions. The discount rate decreased from 5% to 4.5%. Furthermore, the revised guidelines provide more detailed and specific instructions for items including non-inferiority margin, extrapolation, utility elicitation, and uncertainty. Treatment switch and co-dependent technology guidelines are newly included; the budget impact analysis guideline is deleted. Through this revision, transparency and consistency of decision-making is expected to improve. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER INT PUBL AG | - |
dc.relation.isPartOf | APPLIED HEALTH ECONOMICS AND HEALTH POLICY | - |
dc.title | Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000767716500001 | - |
dc.identifier.doi | 10.1007/s40258-022-00721-4 | - |
dc.identifier.bibliographicCitation | APPLIED HEALTH ECONOMICS AND HEALTH POLICY, v.20, no.4, pp.467 - 477 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85126124171 | - |
dc.citation.endPage | 477 | - |
dc.citation.startPage | 467 | - |
dc.citation.title | APPLIED HEALTH ECONOMICS AND HEALTH POLICY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Hong, Jihyung | - |
dc.type.docType | Article | - |
dc.relation.journalResearchArea | Business & Economics | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Economics | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Policy & Services | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.